Your browser doesn't support javascript.
loading
Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.
Harisinghani, M G; Saini, S; Weissleder, R; Rubin, D; deLange, E; Harms, S; Weinreb, J; Small, W; Sukerkar, A; Brown, J J; Zelch, J; Lucas, M; Morris, M; Hahn, P F.
Afiliación
  • Harisinghani MG; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. mharisinghani@partners.org
J Comput Assist Tomogr ; 25(5): 770-6, 2001.
Article en En | MEDLINE | ID: mdl-11584239
PURPOSE: Ferumoxtran-10 (ultrasmall superparamagnetic iron oxide; Combidex, AMI-7227) is a long-circulating MR contrast agent with reticuloendothelial uptake known to enhance tissue T1 and T2 relaxation rates. The purpose of this study was to assess the effect of ferumoxtran-10-enhanced MRI in evaluating focal splenic lesions. METHOD: Eighteen patients underwent MR evaluation of the spleen. Two of these patients with exophytic normal splenic tissue (splenules) and 13 of these patients with 24 focal splenic lesions (7 cysts, 2 hemangiomas, 7 metastases, 1 infarct, 7 lymphoma) were assessed by T1-weighted gradient echo and T2-weighted fast SE MRI following intravenous administration of ferumoxtran-10 (1.1 mg of Fe/kg). Qualitative analysis involving improved lesion detection and/or characterization, additional information from postcontrast images affecting staging, and patient management was performed. Quantitative measurements of lesion-to-spleen contrast-to-noise ratio were also performed. RESULTS: Additional information was provided by ferumoxtran-10-enhanced images in 15 of 18 patients. In 8 of 15 (53%) patients, improved lesion detection (i.e., number of lesions) was obtained on contrast-enhanced images. Improved lesion visualization (i.e., conspicuity) was noted in 11 of 15 (73%) of patients. In 10 of 15 (67%) patients, postcontrast imaging provided additional information leading to lesion characterization. Staging of disease and patient management were affected in 5 of 15 (33%) and 6 of 15 (40%) patients, respectively. CONCLUSION: Ferumoxtran-10 is a promising contrast agent for the evaluation of focal splenic lesions.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Óxidos / Bazo / Enfermedades del Bazo / Medios de Contraste / Hierro Tipo de estudio: Diagnostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Comput Assist Tomogr Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Óxidos / Bazo / Enfermedades del Bazo / Medios de Contraste / Hierro Tipo de estudio: Diagnostic_studies / Qualitative_research Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Comput Assist Tomogr Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos